Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

A new study has developed and validated a predictive model to estimate 5-year renal survival and support early risk stratification for personalized management in

Designed with potential application in primary care settings, the model integrates routinely available clinical and pathological variables to enable early identification of patients at increased risk of disease progression, including in resource-limited environments outside of specialty nephrology centers.

“By facilitating timely risk stratification and supporting evidence-based decision-making, this model may contribute to more precise, proactive, and resource-efficient care in IgAN, ultimately improving long-term outcomes,” wrote study investigator Yongqiang Lin, from the Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, and colleagues. “Further multicenter, prospective studies are warranted to validate its generalizability and support its integration into routine clinical practice.”

Several prediction models have been developed to estimate renal outcomes in IgA nephropathy, including the International IgA Nephropathy Prediction Tool, which is widely used in clinical research settings. In this study, investigators compared the performance of their XGBoost-based model with the IIgANPT using an external validation cohort.

To assess 5-year renal outcomes of IgAN patients, investigators conducted a retrospective cohort study with single-center model development and multicenter external validation, developing an XGBoost-based survival model and a corresponding nomogram.

They collected 1000 bootstrap samples from the training set for variable selection. Variables with non-zero coefficients were recorded, and the 5 most frequently selected were used to construct both the XGBoost survival model and a corresponding nomogram. These include anemia status, estimated glomerular filtration rate stage, hypertension status, Oxford classification T score, and 24-hour urinary total protein.

Investigators randomly assigned patients in a 7:3 ratio to training and internal validation cohorts. They assessed model performance based on discrimination, calibration, and clinical utility using ROC curves, Brier scores, calibration curves, and decision curve analysis. To enable direct comparison with the IIgANPT, investigators performed an additional external validation analysis redefining the endpoint as a ≥50% decline in eGFR.

A total of 1135 patients with biopsy-confirmed IgAN were initially identified at Hangzhou Hospital of Traditional Chinese Medicine, of whom 723 met the inclusion criteria and were included in the training and internal validation cohorts. The external validation cohort comprised 352 patients from 3 independent centers.

Upon analysis, the area under the curve (AUC) was 0.951 (95% CI, 0.914–0.988) in the training cohort, 0.927 (95% CI, 0.877–0.978) in the internal validation cohort, and 0.913 (95% CI, 0.870–0.955) in the external validation cohort. Brier scores were 0.029 and 0.045 for the internal and external validation cohorts, respectively.

When investigators compared the IIgANPT using the ≥50% eGFR decline endpoint with the XGBoost, their model demonstrated increased discriminative performance, achieving an AUC of 0.915 compared to 0.715. Using a ≥40% decline in eGFR as the primary endpoint, investigators noted the model demonstrated increased sensitivity to early disease progression, potentially enabling identification of high-risk patients at an earlier stage.

“An intuitive nomogram derived from the model enables individualized risk assessment at diagnosis, helping primary care physicians recognize high-risk individuals, optimize follow-up strategies, and guide early, personalized management,” concluded investigators.

Wang J, Chen T, Fu Y, et al. Development and preliminary validation of a predictive model for IgA nephropathy progression. Scientific Reports. Published online December 14, 2025. doi:

https://doi.org/10.1038/s41598-025-32280-8

The International IgA NEPHROPATHY Prediction Tool. UK Kidney Association. Published 2021. Accessed December 17, 2025. 

https://www.ukkidney.org/health-professionals/information-resources/international-iga-nephropathy-prediction-tool

Articles

A predictive model has been developed to estimate 5-year renal survival in IgA nephropathy (IgAN), facilitating early risk stratification and personalized management. The model, suitable for primary care settings, uses clinical and pathological variables to identify patients at risk of disease progression, even in resource-limited environments. It outperforms the International IgA Nephropathy Prediction Tool in discriminative performance, with an AUC of 0.915 versus 0.715. The model's nomogram aids primary care physicians in recognizing high-risk patients, optimizing follow-up, and guiding early management strategies.

A retrospective cohort study developed and validated a predictive model for IgA nephropathy, using routinely available variables. 


Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

IgA Nephropathy Prediction Model Aids 5-Year Survival Estimation

Kavita Mariwalla, MD, is a double board-certified dermatologist and a fellowship-trained Mohs surgeon.

Nazanin Saedi, MD, is a board-certified dermatologist and national expert in cosmetic and laser dermatology.

Mona Gohara, MD, is an associate clinical professor of Dermatology at the Yale School of Medicine.

The Medical Sisterhood: Redefining Leadership and Mentorship in Dermatology

, host Mona Shahriari, MD, associate clinical professor of dermatology at the Yale University School of Medicine, brings together a powerhouse panel of women leaders in 

 for a wide-ranging conversation on education, leadership, authenticity, and balance in medicine. Joining Shahriari are Kavita Mariwalla, MD, president of the American Society for Dermatologic Surgery and a double board-certified Mohs surgeon and dermatologist in private practice; Nazanin Saedi, MD, associate professor of dermatology at Thomas Jefferson University Hospitals; and Mona Gohara, MD, associate clinical professor at Yale University School of Medicine’s Department of Dermatology.

The discussion centers on the origins and evolution of Boards University, an educational platform that has become an essential resource for dermatology residents and early-career physicians. Mariwalla recounts how the initiative was born during the COVID-19 shutdown, when residents lost access to traditional in-person teaching and board preparation. Recognizing both an educational gap and an opportunity to re-center dermatology education around substance rather than social media optics, she began hosting live, interactive teaching sessions focused on high-yield content and community building.

The panel reflects on how Boards University quickly grew beyond its initial scope, resonating with learners across training programs and career stages. Gohara and Saedi emphasize that its success lies not only in the quality of the education, but in the authenticity of its delivery—faculty showing up as they are, balancing busy clinical lives, family responsibilities, and teaching in real time. That transparency, they note, helped foster a sense of connection and shared purpose among learners who might otherwise feel isolated.

The conversation also explores broader themes of leadership and career pathways in dermatology. The panel challenges the notion that academic impact is confined to traditional university settings, highlighting how private practice physicians can meaningfully contribute to education, mentorship, and national leadership. Mariwalla underscores the importance of modeling intellectual rigor across all practice settings, noting that excellence in procedural dermatology, general dermatology, and education are not mutually exclusive.

Shahriari guides the discussion toward the realities faced by women physicians, particularly those balancing leadership roles with motherhood and personal responsibilities. The panel speaks candidly about the pressure to “do it all,” acknowledging that perfection is neither attainable nor necessary. Instead, they emphasize adaptability across different seasons of life and career, and the importance of prioritizing what matters most at any given time.

The latter part of the episode lightens in tone as the panel shares practical, realistic approaches to self-care and aesthetic treatments for busy physician-mothers, favoring low-downtime skincare routines and procedures that fit into demanding schedules. These moments add levity while reinforcing the theme of sustainability—professionally and personally.

As the episode closes, each guest reflects on gratitude, growth, and looking ahead. The discussion returns to the core mission of The Medical Sisterhood: creating spaces where women physicians can learn together, support one another, and lead with authenticity. Through education, mentorship, and community, Shahriari and her guests illustrate how collective effort continues to shape the future of dermatology.

Editor’s note: This episode was summarized with the help of artificial intelligence tools.

Want to join The Medical Sisterhood community? Click here to join our LinkedIn Group!

Videos

In this episode, a panel of dermatologists join to discuss the impact of the Boards University educational initiative for residents and early-career physicians.

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Julian Zorrilla, DO, is a pediatric hematologist and oncologist at Nemours Children's Health.

Minor Surgeries Safe to Perform in Patients Receiving Fitusiran Prophylaxis, With Julian Zorrilla, DO

Minor surgeries can be safely conducted for patients receiving fitusiran prophylaxis for 

, regardless of inhibitor status, according to a recent study.

67th American Society of Hematology (ASH) Annual Meeting and Exposition

 by Julian Zorrilla, DO, a pediatric hematologist and oncologist at Nemours Children’s Health, these data emphasize the overall efficacy of fitusiran in hematology at large.

Hemophilia A/B bleeding is caused by deficiencies in factor VIII and factor IX, respectively, which result in insufficient thrombin generation and disrupted hemostasis. Treatment strategies for restoring thrombin generation to achieve hemostasis relied for years on replacing or mimicking the missing factor. However, fitusiran, a subcutaneous prophylactic small-interfering RNA therapeutic, lowers antithrombin levels and increases thrombin generation irrespective of inhibitors.

“One of the things we performed in analysis was to look specifically at what other hemostatic control options investigators had at their disposal, whether that would be regular factor products or products with bypassing agents traditionally used for those with inhibitors,” Zorrilla told 

 in an exclusive interview. “And so, we would take that into account depending on what minor procedures were performed.”

Zorrilla and colleagues examined all minor surgeries in the fitusiran clinical development program prior to June 2023, including patients on the original dose regimen of 80 mg fixed once monthly and the antithrombin-based dose regimen with a starting dose of 50 mg once every 2 months. For inclusion in the study, procedures had to have been conducted during fitusiran prophylaxis and when antithrombin activity was <60%.

Investigators defined minor surgeries as any invasive operative procedure in which only skin, mucous membranes, and/or superficial connective tissue were manipulated. Additionally, perioperative hemostatic control was assessed by the investigators or surgeon based on the ISTH 4-point response scale on the day of the surgery. Perioperative use of antifibrinolytics was reported from the day of the surgery until day 7 post-surgery.

A total of 71 minor surgeries were performed during fitusiran’s clinical development program, encompassing 44 patients. These included dental (n = 21), soft tissue (n = 12), abdominal (n = 12), central or peripheral access-related (n = 10), orthopedic (n = 7), plastic/reconstructive (n = 4), airway management and emergency (n = 3), and ophthalmic (n = 2). Overall, 26 surgeries were performed in patients with hemophilia on the original dose regimen and 45 in patients with hemophilia with the antithrombin-based dose regimen.

Of 22 surgeries with a hemostatic control assessment on the day of the surgery, 21 cases were rated as excellent/goo,d and 1 case was rated as moderate. ATIII concentrate was not used to reverse the pharmacodynamic effect of fitusiran in 99% (n = 70/71) of minor surgeries. Additionally, a total of 67% (n = 14/21) of dental surgeries and 87% (n = 62/71) of all minor surgeries did not require the use of antifibrinolytics.

Ultimately, Zorrilla and colleagues determined that minor surgeries can safely be conducted in patients experiencing fitusiran prophylaxis, regardless of inhibitor status. Most surgeries achieved excellent/good perioperative hemostatic control, based on the ISTH 4-point response scale, and reversal of antithrombin-lowering effects was rarely performed.

“With fitusiran’s thrombogenic profile in ammonium clotting in those with hemophilia, one of the safety measures that we always look at has to relate to the instances of venous thromboembolism in patients while they’re on fitusiran,” Zorrilla said. “This is especially true when they’re going to surgery, whether it be major or minor.”

Editor's Note: Zorrilla reports no relevant disclosures.

Pipe S, Zhu T, Kavakli K, et al. Experience with minor surgeries in people with hemophilia A or B with and without inhibitors receiving fitusiran. Abstract presented at the 67th American Society of Hematology Annual Meeting. Orlando, FL. December 6-9, 2025.

Pipe SW, Lissitchkov T, Georgiev P, et al. Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B. Blood Adv. 2025;9(5):1147-1158. 

Zorrilla discusses the safety and efficacy of a series of minor surgeries in patients with hemophilia A/B currently taking fitusiran to control AT levels.

Hematology

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The American Association for the Study of Liver Diseases (AASLD) and American Society of Transplantation (AST) have released 2 new practice guidelines on evaluating adult liver transplant candidates and managing non-graft complications that drive long-term outcomes following liver transplantation.

“AASLD’s practice guidelines and guidances are invaluable tools for clinicians worldwide. Together, these guidelines represent a comprehensive, patient-centered roadmap for adult liver transplantation,” Grace Su, MD, President of AASLD, said in a statement.

 “By addressing both who should be considered for transplant and how patients should be cared for long after surgery, we aim to support better outcomes, improved quality of life, and more consistent care for patients worldwide.”

Across its 69 guideline statements, the document on candidate evaluation lays out a comprehensive, principle-driven framework for who should be referred for liver transplantation, how candidates should be evaluated, and how risks should be mitigated to maximize post-transplant benefit. Broadly, the statements emphasize early and equitable referral for patients with decompensated cirrhosis, acute-on-chronic liver failure, acute liver failure, and selected liver malignancies.

It emphasizes that MELD score alone should never be a barrier to referral, particularly when portal hypertensive complications or biologically aggressive disease are present. For tumor indications, the statements reinforce careful staging, use of accepted criteria, and selective downstaging or neoadjuvant approaches to identify favorable tumor biology before listing.

The guidelines strongly recommend that transplant evaluation be multidisciplinary and individualized, integrating medical urgency, likelihood of benefit, and patient goals. Statements address standardized cardiopulmonary assessment, infection screening and vaccination, and age-appropriate cancer screening.

Nutritional status, bone health, and physical function are also highlighted as modifiable risk factors that should be routinely assessed, with interventions initiated pre-transplant when feasible.

Many of the statements focus on psychosocial evaluation and substance use, underscoring that transplant candidacy depends on the ability to adhere to care, adequate social support, and access to mental health and addiction treatment rather than arbitrary abstinence thresholds. The document emphasizes that alcohol abstinence duration alone should not determine eligibility, patients on medication-assisted therapy should not be excluded, and ongoing monitoring for substance use is recommended once listed.

Across the guideline statements in this second AASLD/AST adult liver transplantation document, the recommendations again emphasize appropriate candidate selection, rigorous pre-transplant evaluation, and longitudinal management to optimize transplant outcomes and steward scarce organs responsibly. Timely referral, even before advanced decompensation, is repeatedly highlighted as essential to improving waitlist and post-transplant outcomes.

A central theme is the need for standardized yet individualized evaluation, incorporating medical, surgical, and psychosocial domains. The guideline statements recommend comprehensive cardiopulmonary assessment, malignancy screening, infection surveillance, and immunization, alongside evaluation of nutritional status, frailty, and sarcopenia. Particular attention is paid to identifying reversible risk factors and intervening early through medical optimization, rehabilitation, or specialty referral rather than excluding patients outright.

The document also devotes substantial attention to psychosocial considerations, adherence, and substance use, recommending structured assessments of social support, psychiatric comorbidities, and ability to engage in complex post-transplant care.

As in prior guidance, the statements discourage the use of inflexible abstinence rules and instead support individualized, multidisciplinary approaches to alcohol and substance use disorders, including ongoing monitoring and treatment.

Collectively, the guideline statements advocate for equitable access, transparent decision-making, and consistent application of evidence-based principles to ensure that liver transplantation delivers meaningful, durable benefit to patients most likely to achieve long-term success.

AASLD. AASLD and AST Announce Two New Practice Guidelines. December 17, 2025. Accessed December 17, 2025. 

https://www.aasld.org/aasld-and-ast-announce-two-new-practice-guidelines

Dove L, Chadha RM, Lai JC, et al. AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation. Hepatology. doi:10.1097/HEP.0000000000001644

Sharma P, Izzy M, Ghabril M, et al. AASLD AST Practice Guideline on adult liver transplantation: Diagnosis and post-transplant management of non-graft-related complications. Liver Transplantation. doi:10.1097/LVT.0000000000000785

New practice guidelines from AASLD and AST provide a comprehensive framework for evaluating adult liver transplant candidates and managing non-graft complications post-transplant. The guidelines emphasize early and equitable referral, multidisciplinary evaluation, and individualized care to optimize outcomes. Key areas include psychosocial evaluation, substance use management, and modifiable risk factors like nutritional status and bone health. The guidelines advocate for transparent decision-making and evidence-based principles to ensure meaningful, durable benefits for patients. They discourage rigid abstinence rules, promoting ongoing monitoring and treatment for substance use disorders.

AASLD and AST have released 2 new guidelines on evaluating adult liver transplant candidates and managing non-graft complications after transplantation.

Hepatology

AASLD Releases New Liver Transplantation Practice Guidelines on Candidacy, Management

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

The phase 3 VITESSE trial of the VIASKIN® Peanut patch met its primary endpoint in 

 aged 4 to 7 years, DBV Technologies announced December 17, 2025. The lower bound of the 95% confidence interval for the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15%.

“I’m thrilled by these topline results, which show a statistically significant treatment effect in children treated with the VIASKIN Peanut patch,” said lead investigator David Fleischer, MD, professor of pediatrics at Children's Hospital Colorado, in a statement.

 “The levels of desensitization achieved in this study after one year on treatment are highly clinically meaningful and represent substantial progress towards a well-tolerated, non-invasive potential option that I believe would be welcomed into pediatric care.”

The VITESSE phase 3, randomized, double-blind, placebo-controlled multi-site trial enrolled 654 children, with 438 randomized to VIASKIN Peanut and 216 to placebo. The primary endpoint was the difference between the percentage of treatment responders in the active versus placebo arm after 12 months of treatment.

At 12 months, VIASKIN Peanut demonstrated a statistically significant treatment effect (P <.001), with 46.6% of treated children meeting the responder criteria compared with 14.8% in the placebo arm, corresponding to a 31.8% difference in response rates (95% CI, 24.5–39.0), exceeding the pre-specified lower-bound threshold of 15%.

The study defined responders as children who increased their eliciting dose, the amount of peanut protein that induced an allergic reaction, from ≤30 mg at baseline to ≥300 mg of peanut protein at 12 months, or from 100 mg at baseline to ≥600 mg at 12 months, as assessed by double-blind, placebo-controlled food challenge (DBPCFC).

“As a practicing allergist, I look forward to what that may mean for families managing peanut allergy every day and hope to be able to implement this treatment in my clinic, if approved,” Fleischer added.

Safety findings were consistent with previous trials in the VIASKIN Peanut clinical program, with no treatment-related serious adverse events and high compliance (96.2%). The most common treatment-emergent adverse event (TEAE) was mild-to-moderate local skin reactions at the patch application site. TEAE-related discontinuations were low (3.2% in the treatment arm vs 0.5% in the placebo arm).

“We saw tremendous enthusiasm around EPIT and the VIASKIN Peanut patch development program at ACAAI’s annual scientific meeting last month,” said allergist Cherie Zachary, MD, president of the American College of Allergy, Asthma and Immunology (ACAAI).

 “I am excited to see what’s possible with this innovative treatment in 4-7-year-old patients, if approved. I look forward to open-label results in the future to fully understand the potential impact VIASKIN Peanut can have in this age group.”

At ACAAI 2025, HCPLive covered the late-breaking presentation, “Peanut Patch Treatment Continues to Help Toddlers Safely Build Tolerance Over Three Years,” about the open-label extension of the EPITOBE study. The extension followed 56 toddlers who had received a placebo in the initial 1-year trial and subsequently used the peanut patch for up to 3 years. After 3 years of treatment, 71.2% of toddlers tolerated the equivalent of 3 to 4 peanut kernels (≥1000 mg), compared with 62.7% after 1 year.

DBV plans to submit a Biologics License Application (BLA) to the US Food & Drug Administration (FDA) in the first half of 2026.

 The company expects the BLA may be eligible for priority review since the FDA had previously granted VIASKIN Peanut patch a Breakthrough Therapy Designation.

“VITESSE is the largest immunotherapy clinical trial ever conducted in food allergy [with 86 sites across the United States, Canada, the United Kingdom, Europe, and Australia], and we are thrilled that the resulting clinical evidence supporting the VIASKIN Peanut patch is robust,” said Daniel Tassé, Chief Executive Officer of DBV Technologies, in a statement.

 “With these data in hand, I am looking forward to submitting the BLA to the FDA, as planned, in the first half of 2026.”

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years. Globe Newswire. Published December 16, 2025. Accessed December 17, 2025. 

https://www.globenewswire.com/news-release/2025/12/16/3206604/0/en/DBV-Technologies-Announces-Positive-Topline-Results-from-Phase-3-VITESSE-Trial-of-VIASKIN-Peanut-Patch-in-Peanut-Allergic-Children-Aged-4-7-Years.html

Derman C. Over 70% of Toddlers Tolerate 3 to 4 Peanut Kernels 3 Years After Peanut Patch. HCPLive. Published November 21, 2025. 

https://www.hcplive.com/view/over-70-toddlers-tolerate-3-to-4-peanut-kernels-3-years-peanut-patch

The phase 3 VITESSE trial demonstrated that the VIASKIN® Peanut patch significantly improved desensitization in peanut-allergic children aged 4 to 7 years. The trial met its primary endpoint, with a 31.8% difference in response rates between the treatment and placebo groups. Safety findings were consistent with previous studies, showing no serious adverse events. The trial's success supports the potential for a non-invasive treatment option for pediatric peanut allergies. DBV Technologies plans to submit a Biologics License Application to the FDA in 2026, potentially benefiting from priority review.

DBV Technologies announced that the phase 3 VITESSE trial on VIASKIN® Peanut patch for peanut-allergic children met its primary endpoint.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

VIASKIN Peanut Patch Effective in Peanut-Allergic Children Aged 4–7 Years

Haris Sohail, MBBS, is a hematology and oncology fellow at Charleston Area Medical Center.

Sohail discusses the promising results from this retrospective cohort study which aims to put longstanding concerns about worsening infection to bed.

Anemia

IV Iron Reduces Mortality Risk in Iron Deficiency Anemia Without Increasing Infection Severity, With Haris Sohail, MBBS

A meta-epidemiologic study highlights barriers to inclusion of older adults undergoing maintenance dialysis in randomized controlled trials. 


Older Patients on Maintenance Dialysis Underrepresented in RCTs

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Explore the latest advancements in diabetes technology, including updates on CGMs and insulin pumps, enhancing patient care and management.

Type 2 Diabetes

Type 1 Diabetes

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Diabetes Dialogue: 2026 Technology Updates and American Diabetes Association Standards of Care

A large prospective cohort study showed that moderate dietary diversity, particularly greater intake of grains, dairy, vegetables, and fruits, is linked to reduced gout risk.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Gout

On the HCPLive gout page, resources on the topics of medical news and expert insight into gouty arthritis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on gout, and more.

Dietary Diversity With Dairy, Fruit, Grains Linked to Lower Gout Risk 

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Topline findings from the phase 2b REZOLVE-AA trial highlight the efficacy of rezpegaldesleukin in severe-to-very-severe alopecia areata.

Alopecia

REZOLVE-AA: Phase 2b Data Released on Rezpegaldesleukin for Alopecia Areata

Video Series

Expert Perspectives on the Reasons for Diagnostic Delay in GCA

Jason Hawkes, MD, MS, envisions the future of CSU management, highlighting the integration of precision medicine and targeted therapies to individualize care.




Personalization of CSU Care With Advanced Therapies

Diagnostic Blood Testing in GCA

Depemokimab-ulaa is the first and only ultra-long-acting biologic with twice-yearly dosing for patients with severe asthma with an eosinophilic phenotype.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

FDA News

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

New data links chronic pain to impaired muscle relaxation, with the greatest limitations observed in fibromyalgia and chronic tension-type headache.

Pain

The HCPLive pain page is a resource for medical news and expert insights on pain medicine. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for acute pain, chronic pain, addiction medicine, and more.

Chronic Pain

On the HCPLive chronic pain page, resources on the topics of medical news and expert insight into pain treatment can be found. Content includes articles, interviews, videos, podcasts, and breaking news on chronic pain, and more.

Fibromyalgia

On the HCPLive fibromyalgia page, resources on the topics of medical news and expert insight into fibrositis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on fibromyalgia, and more.

Latest News

IgA Nephropathy Prediction Model Aids 5-Year Survival Estimation

The Medical Sisterhood: Redefining Leadership and Mentorship in Dermatology

Minor Surgeries Safe to Perform in Patients Receiving Fitusiran Prophylaxis, With Julian Zorrilla, DO

AASLD Releases New Liver Transplantation Practice Guidelines on Candidacy, Management

VIASKIN Peanut Patch Effective in Peanut-Allergic Children Aged 4–7 Years